Etanercept biosimilar - Shanghai Fudan-Zhangjiang Bio-PharmaceuticalAlternative Names: Recombinant human TNF receptor p75-Fc fusion protein
Latest Information Update: 14 May 2015
At a glance
- Originator Shanghai Fudan-Zhangjiang Bio-Pharmaceutical
- Class Antirheumatics; Disease-modifying antirheumatics; Recombinant fusion proteins
- Mechanism of Action Tumour necrosis factor inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preregistration Rheumatoid arthritis
Most Recent Events
- 15 Mar 2016 Biomarkers information updated
- 12 May 2015 Preregistration for Rheumatoid arthritis in China (Parenteral) before May 2015